Last reviewed 2026-04-19 · How we verify

CD5024 1% cream

Galderma R&D · Phase 2 active Small molecule

CD5024 1% cream is a Small molecule drug developed by Galderma R&D. It is currently in Phase 2 development.

CD5024 1% cream, developed by Galderma R&D, is a topical treatment for papulopustular rosacea and acne vulgaris. It has completed multiple Phase 3 trials and shows promise in reducing inflammatory lesions. The drug is not yet FDA-approved but has demonstrated efficacy and safety in clinical studies.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CD5024 1% cream
Sponsor	Galderma R&D
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CD5024 1% cream CI brief — competitive landscape report
CD5024 1% cream updates RSS · CI watch RSS
Galderma R&D portfolio CI

Frequently asked questions about CD5024 1% cream

What is CD5024 1% cream?

CD5024 1% cream is a Small molecule drug developed by Galderma R&D.

Who makes CD5024 1% cream?

CD5024 1% cream is developed by Galderma R&D (see full Galderma R&D pipeline at /company/galderma-r-d).

What development phase is CD5024 1% cream in?

CD5024 1% cream is in Phase 2.

Manufacturer: Galderma R&D — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing